Actively Recruiting
Study of Autologous Platelet-rich Plasma and Artificial Tears Eye Drops for Treating Neurotrophic Keratopathy
Led by Universidad Autonoma de Nuevo Leon · Updated on 2026-05-06
39
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Neurotrophic keratopathy NK is a chronic eye condition where the cornea loses its ability to sense pain and touch, leading to slower wound healing and potential corneal damage. This research aims to find out if a combination of autologous platelet-rich plasma APRP and preservative-free artificial tears PFAT is more effective than either treatment alone for NK. The study is randomized and supervised by Universidad Autonoma de Nuevo Leon to evaluate the best treatment approach for this condition. Participants will be randomly assigned to one of three groups receiving eye drops PFAT alone, APRP alone, or both combined. Each treatment period lasts four weeks, followed by switching to the next treatment, resulting in a 12-week total treatment time. Eye drops are applied every two hours in the affected eye. Treatment will stop if adverse effects or intolerance occur. Throughout the study, participants will undergo thorough eye exams every four weeks to assess corneal staining, sensitivity, tear stability, eye surface health, tear osmolarity, tear production, vision quality, and quality of life. Adverse events will be monitored closely. This detailed follow-up helps researchers understand how each treatment affects the eye and patient well-being over the full 12 weeks.
CONDITIONS
Brief Title
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
Research Team
K
Karim Mohamed-Noriega, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here